Status:
UNKNOWN
Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
Lead Sponsor:
Hospital Mutua de Terrassa
Conditions:
Microscopic Colitis
Colorectal Cancer
Eligibility:
All Genders
45+ years
Brief Summary
Microscopic colitis (MC) is an inflammatory bowel disease characterized by chronic non-bloody watery diarrhoea and a macroscopically normal colonic mucosa upon endoscopic exploration (colonoscopy). Th...
Eligibility Criteria
Inclusion
- MC and Chronic watery diarrhea patients
- Women ≥ 45 years old / Men ≥ 60 years old.
- Patient with chronic watery diarrhea without blood with ≥2 liquid stools per day for minimum 3 times a week and lasting at least 1 month.
- Blood analysis values within normality, with negative celiac disease serology and absence of acute phase reactants (normal C-reactive protein) and normal thyroid hormones. Calprotectin values may be elevated.
- Signing of the informed consent.
- Patients with Advanced Colon Adenomas
- Age between 50 and 70 years.
- Population screening participants with polyps with a crypt pattern of adenomatous appearance and polyp size of ≥10mm, or patients referred for endoscopic treatment of advanced adenomas.
- Signing of the informed consent.
- Healthy controls
- 1\. Age between 50 and 70 years. 2. Participants in the population screening with normal colonoscopy (without endoscopic alterations except presence of \< 5 polyps (all less than 10mm) and/or colonic diverticulosis (except multiple diverticula in the sigma)). 3. Signing of the informed consent.
Exclusion
- Pregnancy or breastfeeding.
- Patients who have received antibiotic, probiotic or prebiotic treatment in the 3 months prior to the study. 3. Patients who have traveled to developing or underdeveloped countries in the 3 months prior to the start of the study.
- 4\. Patients who have received immunosuppressants and corticosteroids in the 3 months prior to the start of the study.
- 5\. Patients who have received radiotherapy and/or chemotherapy in the 6 months prior to the start of the study.
- 6\. Consumption of herbal products. 7. Bacterial or parasitic intestinal infection (including Blastocystis hominis).
- 8\. History of inflammatory bowel disease or celiac disease. 9. Previous gastrointestinal surgery (excluding appendectomy or inguinal hernia repair).
- 10\. Incomplete colonoscopy or lack of biopsies of the right, transverse and left colon.
- 11\. Unsatisfactory preparation for a complete examination (Boston scale \<6, any segment \<2).
- 12\. Inability to understand the instructions involved in participating in this study
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06172647
Start Date
June 1 2022
End Date
June 30 2025
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari MútuaTerrassa
Terrassa, Barcelona, Spain, 08221